The use of bio oil from at least one renewable source in a hydrotreatment process, in which process hydrocarbons are formed from said glyceride oil in a catalytic reaction, and the iron content of said bio oil is less than 1 w-ppm calculated as elemental iron. A bio oil intermediate including bio oil from at least one renewable source and the iron content of said bio oil is less than 1 w-ppm calculated as elemental iron.

The use of bio oil from at least one renewable source in a hydrotreatment process, in which process hydrocarbons are formed from said glyceride oil in a catalytic reaction, and the iron content of said bio oil is less than 1 w-ppm calculated as elemental iron. A bio oil intermediate including bio oil from at least one renewable source and the iron content of said bio oil is less than 1 w-ppm calculated as elemental iron.

Disclosed are compounds of formula (I)

(R.sup.1OOC).sub.aR.sup.2(OH).sub.cCOO(C.sub.nH.sub.2nO).sub.mOCR.sup.3(OH).sub.d(COOR.sup.4).sub.b(I)

wherein R.sup.1 and R.sup.4 independently of one another are hydrogen, a metal cation, an ammonium cation, C.sub.1-C.sub.6-alkyl, cycloalkyl with three to nine ring carbon atoms, aryl with five to ten ring carbon atoms, aryl that is substituted with one or two alkyl groups, aryl that is connected via an alkylene group with the carboxyl group, (C.sub.nH.sub.2nO).sub.mH or OR.sup.2(COOR1).sub.a+1,
R.sup.2 and R.sup.3 independently of one another are aliphatic hydrocarbon residues with one to eight carbon atoms,
a and b independently of one another are integers from 1 to 4,
c is an integer from 0 to 4,
d is an integer from 1 to 4,
n is 2, 3 or 4, and
m is 1, 2, 3 or 4, with the proviso that
R.sup.1 and R.sup.4 may be different within a molecule within the given definitions.

These compounds are characterized by a very good complexation power for metal cations and can be used in detergents and cleaning agents, in oil extraction and for water softening.

Disclosed are compounds of formula (I)

(R.sup.1OOC).sub.aR.sup.2(OH).sub.cCOO(C.sub.nH.sub.2nO).sub.mOCR.sup.3(OH).sub.d(COOR.sup.4).sub.b(I)

wherein R.sup.1 and R.sup.4 independently of one another are hydrogen, a metal cation, an ammonium cation, C.sub.1-C.sub.6-alkyl, cycloalkyl with three to nine ring carbon atoms, aryl with five to ten ring carbon atoms, aryl that is substituted with one or two alkyl groups, aryl that is connected via an alkylene group with the carboxyl group, (C.sub.nH.sub.2nO).sub.mH or OR.sup.2(COOR1).sub.a+1,
R.sup.2 and R.sup.3 independently of one another are aliphatic hydrocarbon residues with one to eight carbon atoms,
a and b independently of one another are integers from 1 to 4,
c is an integer from 0 to 4,
d is an integer from 1 to 4,
n is 2, 3 or 4, and
m is 1, 2, 3 or 4, with the proviso that
R.sup.1 and R.sup.4 may be different within a molecule within the given definitions.

These compounds are characterized by a very good complexation power for metal cations and can be used in detergents and cleaning agents, in oil extraction and for water softening.

The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II and formula III and the methods for the treatment of neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurological diseases.

The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II and formula III and the methods for the treatment of neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurological diseases.

The present invention provides a fatty glyceride preparation method, comprising converting fatty acid short-chain alcohol ester into fatty glyceride basic mixture by sequentially carrying out a normal-pressure reaction and a vacuum reaction in the nitrogen condition in the temperature of 80 C. to 150 C.; and meanwhile adding a basic catalyst and glycerin or adding a basic catalyst and a glycerin derivative into the fatty acid short-chain alcohol ester, so as to implement a conversion from the fatty acid short-chain alcohol ester to the fatty glyceride. Conditions of the preparation method are relatively moderate, and the structure of the fatty acid is not damaged in the reactions; the yield of the glyceride is high, compositions of the glyceride are stable and controllable, glyceride products having a high content of triacylglycerol can be obtained; the process is simple, costs are low, and the fatty glyceride is applicable to industrial production.

The present invention provides a fatty glyceride preparation method, comprising converting fatty acid short-chain alcohol ester into fatty glyceride basic mixture by sequentially carrying out a normal-pressure reaction and a vacuum reaction in the nitrogen condition in the temperature of 80 C. to 150 C.; and meanwhile adding a basic catalyst and glycerin or adding a basic catalyst and a glycerin derivative into the fatty acid short-chain alcohol ester, so as to implement a conversion from the fatty acid short-chain alcohol ester to the fatty glyceride. Conditions of the preparation method are relatively moderate, and the structure of the fatty acid is not damaged in the reactions; the yield of the glyceride is high, compositions of the glyceride are stable and controllable, glyceride products having a high content of triacylglycerol can be obtained; the process is simple, costs are low, and the fatty glyceride is applicable to industrial production.

The compound is represented by general formula (i). In the compound, in a group K.sup.i1, at least two secondary carbon atoms in an alkyl group (a linear alkyl, halogenated alkyl, or cyanogenated alkyl group having 3 to 40 carbon atoms) are replaced with C(X.sup.i1) and/or CH(CN), where X.sup.i1 is an oxygen atom, a sulfur atom, NH, or NR.sup.13; in addition, a group A.sup.i2, a group A.sup.i3, or the group K.sup.i1 includes, as a substituent, at least one P.sup.i1-Sp.sup.i1- group, where P.sup.i1 is a polymerizable group, and SP.sup.i1 is a spacer group or a single bond. The liquid crystal composition including the compound represented by general formula (i) can be adsorbed onto substrates between which a liquid crystal layer is held, and, consequently, without the use of an alignment film, liquid crystal molecules can be maintained in a state in which the liquid crystal molecules are aligned in a vertical direction.

##STR00001##

The compound is represented by general formula (i). In the compound, in a group K.sup.i1, at least two secondary carbon atoms in an alkyl group (a linear alkyl, halogenated alkyl, or cyanogenated alkyl group having 3 to 40 carbon atoms) are replaced with C(X.sup.i1) and/or CH(CN), where X.sup.i1 is an oxygen atom, a sulfur atom, NH, or NR.sup.13; in addition, a group A.sup.i2, a group A.sup.i3, or the group K.sup.i1 includes, as a substituent, at least one P.sup.i1-Sp.sup.i1- group, where P.sup.i1 is a polymerizable group, and SP.sup.i1 is a spacer group or a single bond. The liquid crystal composition including the compound represented by general formula (i) can be adsorbed onto substrates between which a liquid crystal layer is held, and, consequently, without the use of an alignment film, liquid crystal molecules can be maintained in a state in which the liquid crystal molecules are aligned in a vertical direction.

##STR00001##